AzTrials
AzTrials

Carpal Tunnel Syndrome (CTS)NCT07498998

Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome

A study testing Perineural injection with 5% dextrose (D5W)., Local ozone injection and Local glucocorticoid injection (dexamethasone). in people with Carpal Tunnel Syndrome (CTS) and Glucocorticoid, run by Tanta University at 1 site in Egypt.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

This study aims to compare the efficacy and outcomes of perineural injection with 5% dextrose, local ozone and glucocorticoid injection in the management of carpal tunnel syndrome. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Carpal Tunnel Syndrome (CTS), Glucocorticoid, Pain
What is being tested?
Perineural injection with 5% dextrose (D5W)., Local ozone injection and Local glucocorticoid injection (dexamethasone).
Type of treatment
Injection or infusion
Could I receive a placebo?
No, everyone receives an active treatment
How many people
105 participants
Where
1 siteEgypt
Study dates
30 Jul 2026to 30 Aug 2026
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adults aged 18-65 years with a clinical diagnosis of mild to moderate Carpal Tunnel Syndrome .
  • Clinical diagnosis of mild to moderate Carpal Tunnel Syndrome , as classified by Bland neurophysiological classification scale: Mild Carpal Tunnel Syndrome : Slow Distal Sensory Latency(≥3.6 ms), Normal Distal Motor Latency(< 4.5 ms)
  • Moderate Carpal Tunnel Syndrome : Slow Distal Sensory Latency (≥ 3.6 ms), Slow Distal Motor Latency (4.5 - 6.4 ms)
  • Failure to respond to conservative treatments (e.g., splinting, activity modification, or oral medications) for at least 6 weeks.

Who cannot join

  • Patient refusal.
  • Severe Carpal Tunnel Syndrome requiring surgical intervention, as defined by the Bland neurophysiological classification scale: Severe Carpal Tunnel Syndrome: Absent Distal Sensory Latency and Slow Distal Motor Latency (4.5 - 6.4 ms)
  • Previous corticosteroid injection for Carpal Tunnel Syndrome within the last 6 months.
  • History of wrist trauma, surgery or anatomical abnormalities.
  • Systemic conditions such as diabetes mellitus, thyroid dysfunction or rheumatoid arthritis.
  • Pregnancy or lactation.
  • Contraindications to any of the study interventions (e.g., allergy to glucocorticoids or ozone).
  • Infection at wrist.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Tasnim Ayad, Resident contact

+20 10 12537424

tasnimayad15@gmail.com

Tasnim Ayad, Resident contact

Egypt1 site
  • Tanta University

    Tanta

    Tasnim Ayad, Resident, +20 10 12537424, tasnimayad15@gmail.com

Other trials in Egypt

About this study

Official title: A Comparative Study Between Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome

This study aims to compare the efficacy and outcomes of perineural injection with 5% dextrose, local ozone and glucocorticoid injection in the management of carpal tunnel syndrome.

Read the detailed description

Carpal Tunnel Syndrome is one of the most common peripheral entrapment neuropathies caused by compression of the median nerve within the carpal tunnel. This condition manifests as pain, numbness, tingling, and weakness, primarily in the thumb, index, and middle fingers. The condition significantly impairs daily activities and diminishes the quality of life, often prompting patients to seek medical interventions .

The pathophysiology of Carpal Tunnel Syndrome involves increased pressure within the carpal tunnel, leading to ischemia and dysfunction of the median nerve. Risk factors include repetitive wrist motions, systemic diseases like diabetes and rheumatoid arthritis, obesity, and hormonal changes during pregnancy .Early identification and treatment are essential to prevent irreversible nerve damage and functional impairment .

Traditional management strategies for Carpal Tunnel Syndrome vary depending on the severity of symptoms. Conservative approaches, including wrist splinting, activity modification, and physical therapy, are typically recommended for mild to moderate cases . However, these methods often provide limited relief, and invasive treatments, such as corticosteroid injections or surgical decompression, may be required for advanced or refractory cases .

In recent years, less invasive alternatives like perineural injection therapies have gained attention as promising options for carpal Tunnel Syndrome management . These therapies aim to reduce inflammation, relieve nerve compression, and promote tissue healing. The substances under investigation in this study include 5% dextrose, ozone, and glucocorticoids .

Dextrose acts as a neuroprotective and anti-inflammatory agent by modulating nociceptive pathways .It promotes tissue repair through proliferative and regenerative mechanisms, reducing local pain and inflammation. While hyperosmolar dextrose solutions may stabilize nerve function by deterring the release of pro-inflammatory cytokines, the effects of Dextrose 5% are primarily attributed to its role as an energy source for neuronal cells and its involvement in metabolic processes associated with neural repair.

Ozone, when used in medical-grade concentrations, exhibits potent anti-inflammatory and antioxidative effects. It neutralizes reactive oxygen species, reduces oxidative stress, and improves local oxygenation. These effects can enhance nerve function and reduce ischemia within the carpal tunnel .

Glucocorticoids, such as dexamethasone, exert their effects by suppressing local inflammatory responses. They inhibit the release of pro-inflammatory mediators, such as prostaglandins and cytokines, providing rapid symptom relief. However, their short-term efficacy and potential for symptom recurrence necessitate careful evaluation.

Despite the availability of these treatments, there is a lack of robust comparative studies to determine their relative efficacy and outcomes. This research aims to fill this gap by comparing the effectiveness of perineural injections with 5% dextrose, local ozone, and glucocorticoids in the management of Carpal Tunnel Syndrome.

Primary outcomes

  • Evaluation of electrodiagnostic parameters (median nerve distal motor latency and sensory conduction velocity) at 3 months.

Secondary outcomes

  • Evaluation of analgesic efficacy of Dextrose 5%, Ozone and Glucocorticoid local injection in carpal tunnel syndrome via assessment of Visual Analog Scale pain scores after injection by 1 and 3 months.
  • Evaluation of Analgesic drugs requirement.
Being tested
Perineural injection with 5% dextrose (D5W)., Local ozone injection, Local glucocorticoid injection (dexamethasone).
Keywords
glucocorticoid, Ozone, 5% dextrose, carpal tunnel syndrome
Medical subject headings
Carpal Tunnel Syndrome, Pain

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Perineural injection with 5% dextrose (D5W).Drug

    Group 1: Perineural injection with 5% dextrose (D5W).

  • Local ozone injectionDrug

    Group 2: Local ozone injection

  • Local glucocorticoid injection (dexamethasone).Drug

    Group 3: Local glucocorticoid injection (dexamethasone).

Study groups in NCT07498998
Study groupRoleWhat they receive
Group 1ExperimentalPerineural injection with 5% dextrose
Receives: Drug: Perineural injection with 5% dextrose (D5W).
Group 2ExperimentalLocal ozone injection
Receives: Drug: Local ozone injection
Group 3ExperimentalLocal glucocorticoid injection
Receives: Drug: Local glucocorticoid injection (dexamethasone).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. median nerve distal motor latency

    Measured: 3 months

Secondary outcomes (1)
  1. Evaluation of analgesic efficacy via assessment of Visual Analog Scale

    Measured: At 1 and 3 months.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Mar 2026
  2. Study start30 Jul 2026 (estimated)
  3. Primary completion30 Aug 2026 (estimated)
  4. Study completion30 Aug 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
105 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07498998
Sponsor's protocol ID
36264MS877/3/25
Status last verified
Jul 2025
First submitted
6 Feb 2026
Last updated
27 Mar 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All data were available if it needed

Questions about this trial

What is this clinical trial studying?

A study testing Perineural injection with 5% dextrose (D5W)., Local ozone injection and Local glucocorticoid injection (dexamethasone). in people with Carpal Tunnel Syndrome (CTS) and Glucocorticoid, run by Tanta University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Tasnim Ayad, Resident (+20 10 12537424, tasnimayad15@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

median nerve distal motor latency (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT07498998 | AzTrials